Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catheter Precision (VTAK) EBITDA (2017 - 2025)

Historic EBITDA for Catheter Precision (VTAK) over the last 9 years, with Q3 2025 value amounting to -$3.0 million.

  • Catheter Precision's EBITDA fell 566.63% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.3 million, marking a year-over-year decrease of 3284.83%. This contributed to the annual value of -$11.2 million for FY2024, which is 8560.79% up from last year.
  • Catheter Precision's EBITDA amounted to -$3.0 million in Q3 2025, which was down 566.63% from -$4.7 million recorded in Q2 2025.
  • In the past 5 years, Catheter Precision's EBITDA ranged from a high of -$2.6 million in Q4 2023 and a low of -$66.5 million during Q1 2023
  • Its 5-year average for EBITDA is -$8.3 million, with a median of -$4.8 million in 2022.
  • In the last 5 years, Catheter Precision's EBITDA crashed by 110814.1% in 2023 and then soared by 9606.52% in 2024.
  • Catheter Precision's EBITDA (Quarter) stood at -$8.3 million in 2021, then rose by 0.59% to -$8.2 million in 2022, then skyrocketed by 68.39% to -$2.6 million in 2023, then decreased by 17.48% to -$3.1 million in 2024, then grew by 0.98% to -$3.0 million in 2025.
  • Its EBITDA stands at -$3.0 million for Q3 2025, versus -$4.7 million for Q2 2025 and -$3.6 million for Q1 2025.